RESUMEN
The expression of fibroblast growth factor receptor (FGFR)-1 correlates with angiogenesis and is associated with prostate cancer (CaP) progression. To more precisely define the molecular mechanisms whereby FGFR1 causes angiogenesis in the prostate we exploited a transgenic mouse model, JOCK-1, in which activation of a conditional FGFR1 allele in the prostate epithelium caused rapid angiogenesis and progressive hyperplasia. By labeling the vasculature in vivo and applying a novel method to measure the vasculature in three dimensions, we were able to observe a significant increase in vascular volume 1 week after FGFR1 activation. Although vessel volume and branching both continued to increase throughout a 6-week period of FGFR1 activation, importantly, we discovered that continued activation of FGFR1 was not required to maintain the new vasculature. Exploring the molecular mediators of the angiogenic phenotype, we observed consistent upregulation of HIF-1alpha, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), whereas expression of Ang-1 was lost. Further analysis revealed that loss of Ang-1 expression occurred in the basal epithelium, whereas the increase in Ang-2 expression occurred in the luminal epithelium. Reporter assays confirmed that the Ang-2 promoter was regulated by FGFR1 signaling and a small molecule inhibitor of FGFR activity, PD173074, could abrogate this response. These findings establish a method to follow spontaneous angiogenesis in a conditional autochthonous system, implicate the angiopoietins as downstream effectors of FGFR1 activation in vivo, and suggest that therapies targeting FGFR1 could be used to inhibit neovascularization during initiation and progression of CaP.
Asunto(s)
Angiopoyetina 1/metabolismo , Angiopoyetina 2/biosíntesis , Neovascularización Fisiológica , Próstata/irrigación sanguínea , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/metabolismo , Angiopoyetina 1/análisis , Angiopoyetina 2/análisis , Angiopoyetina 2/genética , Animales , Línea Celular , Epitelio/metabolismo , Masculino , Ratones , Ratones Transgénicos , Próstata/metabolismo , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/genética , Transducción de Señal , Activación TranscripcionalRESUMEN
BACKGROUND: The frequency and clinical relevance of human antitumor immune responses is not well known, and few target antigens have been identified. PURPOSE: This study was designed to determine the frequency of antibodies reactive against extracts of autologous tumor cell lines and to correlate these data with survival. METHODS: Serum samples were obtained from 40 lung cancer patients treated on National Cancer Institute protocols. These sera were used as probes in immunoblots against protein extracts from tumor cell lines derived from each of these patients. RESULTS: We detected serum antibodies against autologous tumor cell proteins in 21 (58%) of the 36 patients with small-cell lung cancer (SCLC) and three (75%) of the four with non-small-cell lung cancer (NSCLC). Two patients' sera detected the p53 tumor suppressor gene product and two detected the product of the HuD gene (associated with paraneoplastic neurological syndromes) in their autologous tumor cell lysates. SCLC patients with antibodies against autologous tumor cell proteins had improved survivals compared with those in the antibody-negative group (P = .059). All patients who lived longer than 36 weeks were antitumor antibody positive. Sera from six (86%) of seven patients with limited disease were positive for antibodies that reacted against autologous tumor cells, compared with 15 of 29 (52%) of sera from patients with extensive disease. CONCLUSIONS: Our results suggest that the sera from patients with SCLC frequently contain antibodies against tumor cell proteins and that these antibodies are associated with improved survival. IMPLICATIONS: These data suggest that an antitumor immune response may affect tumor growth, and that the anonymous proteins detected by antitumor antibodies in lung cancer patient sera may represent proteins involved in the development of lung cancer or in its clinical manifestations.
Asunto(s)
Anticuerpos Antineoplásicos/sangre , Autoanticuerpos/sangre , Carcinoma de Células Pequeñas/inmunología , Neoplasias Pulmonares/inmunología , Proteínas de Neoplasias/inmunología , Anticuerpos Antineoplásicos/biosíntesis , Autoanticuerpos/biosíntesis , Carcinoma de Pulmón de Células no Pequeñas/inmunología , Carcinoma de Células Pequeñas/mortalidad , Humanos , Neoplasias Pulmonares/mortalidad , Pronóstico , Análisis de Regresión , Análisis de SupervivenciaRESUMEN
Using immunoblotting techniques we studied the sera from small cell lung cancer and non-small cell lung cancer patients for antibodies directed against p53. We have also characterized the majority of these patients' tumors for p53 mutations. In the sera of 13% of the patients (4 of 40 small cell lung cancer and 2 of 6 non-small cell lung cancer) we found antibodies specific for the p53 tumor suppressor gene product. All of the antibody-positive patients tested had p53 missense mutations and expressed detectable p53 antigen in their tumor cell lines. No anti-p53 antibodies were detected in sera from patients whose tumor had p53 stop, splice/stop, splice, or frameshift mutations (n = 10). Thus, while we find that the ability of lung cancer patients to develop anti-p53 antibodies is correlated with the type of p53 mutation, many patients have tumors with missense p53 mutations and did not develop anti-p53 antibodies. The presence of p53 antibodies was not correlated to stage, prior treatment, sex, or survival. None of these lung cancer patient sera had measurable amounts of p53 antigen. By immunoblotting all six anti-p53 antisera we were able to detect a variety of mutant p53 proteins (including those from antibody-negative patients) and detected wild-type p53 protein. The development of anti-p53 antibodies represents an interesting model system for studying immune responses in cancer patients against mutant oncogene products.
Asunto(s)
Anticuerpos Antineoplásicos/inmunología , Genes p53 , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/inmunología , Mutación , Proteína p53 Supresora de Tumor/inmunología , Adenocarcinoma/genética , Adenocarcinoma/inmunología , Adenocarcinoma/patología , Adenocarcinoma Bronquioloalveolar/genética , Adenocarcinoma Bronquioloalveolar/inmunología , Adenocarcinoma Bronquioloalveolar/patología , Adulto , Anciano , Anticuerpos Antiidiotipos/análisis , Carcinoma de Células Pequeñas/genética , Carcinoma de Células Pequeñas/inmunología , Carcinoma de Células Pequeñas/patología , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/inmunología , Carcinoma de Células Escamosas/patología , Línea Celular , Femenino , Humanos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Proteína p53 Supresora de Tumor/genéticaRESUMEN
Cytotoxic T-lymphocytes (CTL) recognize processed peptide fragments of any endogenous protein, after these peptides are carried to the cell surface by class I major histocompatibility molecules. Thus, a tumor antigen does not have to be expressed as an intact protein on the cell surface to be recognizable by CTL. However, mutant oncogene products have not yet been shown to be targets of CD8+ CTL. Here, we generate p53-specific CD8+ CTL by immunizing BALB/c mice with spleen cells pulsed with a peptide, corresponding to a 21-amino acid sequence encompassing a point mutation (135 Cys to Tyr) in the mutant p53 gene product from a human lung carcinoma. The mutation created a new Kd class I molecule binding motif sequence, and the determinant recognized was mapped to this motif and presented by the Kd class I molecule. The wild type peptide, without the mutation, was not recognized. Importantly, the CTL killed specifically BALB/c fibroblasts transfected with the mutant p53 gene and endogenously expressing the mutant protein, but not control fibroblasts or ones transfected with a different human mutant p53 gene. Thus, endogenously synthesized mutant p53, at levels found in tumors, can render cells targets for specific CTL, and these CTL can be generated by peptide immunization. These findings point the way toward an approach to selective immunotherapy against tumors.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/genética , Epítopos/inmunología , Neoplasias Pulmonares/genética , Mutación Puntual , Linfocitos T Citotóxicos/inmunología , Proteína p53 Supresora de Tumor/inmunología , Células 3T3 , Secuencia de Aminoácidos , Animales , Antígenos de Histocompatibilidad Clase I/inmunología , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Proteína p53 Supresora de Tumor/genéticaRESUMEN
PURPOSE: Transgenic mouse models are proving to be invaluable in our effort to understand the molecular basis of metastatic prostate cancer (CaP). We review and discuss how current animal models have contributed to our understanding of the metastatic cascade and how transgenic technology is being used to develop the next generation of mouse models. Our goal is to provide a review of the recent advances and provide a framework for further studies. MATERIALS AND METHODS: We performed a MEDLINE search of the literature on CaP metastasis transgenic and animal models. RESULTS: We present a summary of the characteristics of nine different animal models of CaP. Each model is unique and provides valuable insight into the molecular mechanisms governing the progression of CaP. Our experience with transgenic models and all the new data from the literature predicts that we will be able to develop genetically engineered mice that accurately mimic the heterogeneity, androgen-independent growth, and metastatic spread seen in clinical disease. CONCLUSION: In order to elucidate the molecular mechanisms of CaP metastasis, it will be necessary to compare gene and protein expression patterns and biochemical analyses of clinical metastatic disease with data obtained from current models. We will also need to refine our ability to engineer and characterize genetic perturbation models. This type of integrative and iterative approach should facilitate better understanding of the molecular biology of CaP metastases.
Asunto(s)
Modelos Animales de Enfermedad , Metástasis de la Neoplasia/patología , Próstata/patología , Neoplasias de la Próstata/patología , Animales , Animales Modificados Genéticamente , Humanos , Masculino , Metástasis de la Neoplasia/genética , Próstata/metabolismo , Neoplasias de la Próstata/inducido químicamente , Neoplasias de la Próstata/genéticaRESUMEN
Infectious diseases are among the major global health threats. Although associated with these diseases there are vast ethical challenges, ethics has more focused on other health related issues--e.g., associated with rare diseases, embryo research, genetic diagnosis. Nowadays we are facing a possible influenza pandemic caused by a new human influenza virus subtype. This article presents issues and ethical challenges of the pandemic threat. The authors argue that it is necessary to consider ethical implications of pandemic influenza preparedness early on and to include ethical reasoning when deciding on the measures for the pandemic management.
Asunto(s)
Brotes de Enfermedades/prevención & control , Salud Global , Política de Salud , Gripe Humana/epidemiología , Gripe Humana/prevención & control , Salud Pública/ética , Europa (Continente) , Alemania , Humanos , Justicia Social , ConfianzaRESUMEN
Prevention and health promotion are rewarding investments to stabilize our health security systems. They yield sustainable social and individual profit. This is precisely one of the explicitly declared aims of the government's coalition agreement of October 2002 - to upgrade and extend prevention and health promotion in Germany. The Federal Ministry of Health and Social Security is initiating measures and strategies to improve the framework for effective prevention and health promotion, for instance by initiating measures in the field of legislation and by establishing the German Platform for Prevention und Health Promotion.
Asunto(s)
Promoción de la Salud/tendencias , Programas Nacionales de Salud/tendencias , Servicios Preventivos de Salud/tendencias , Adolescente , Adulto , Niño , Diabetes Mellitus Tipo 2/economía , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/prevención & control , Predicción , Alemania , Promoción de la Salud/economía , Promoción de la Salud/legislación & jurisprudencia , Necesidades y Demandas de Servicios de Salud/economía , Necesidades y Demandas de Servicios de Salud/legislación & jurisprudencia , Necesidades y Demandas de Servicios de Salud/tendencias , Encuestas Epidemiológicas , Humanos , Legislación como Asunto/tendencias , Infarto del Miocardio/economía , Infarto del Miocardio/epidemiología , Infarto del Miocardio/prevención & control , Programas Nacionales de Salud/economía , Programas Nacionales de Salud/legislación & jurisprudencia , Servicios Preventivos de Salud/economía , Servicios Preventivos de Salud/legislación & jurisprudenciaRESUMEN
Somatic gene therapy is one of the most fascinating and important medical developments as well as a field bearing unknown risks in human medicine of the nineties. This article tries to give a short survey on the medical applications of this new technique on the one hand and reflects possible ethical and legal implications on the other hand. We conclude that only an international agreement on risk assessment and ethical principles will lead to a adequate approach to somatic gene therapy.